Find Funding Opportunities

NIH Extramural Response to Natural Disasters and Other Emergencies

In emergency situations, the NIH’s immediate concern is for the health and safety of people and animals in the programs we oversee.  Visit the NIH Extramural Response to Natural Disasters and Other Emergencies web page for biomedical research community resources, including NIH Guide Notices and other information of particular relevance to investigators and their institutions, links to web pages listing NIH’s response to certain major events (past and present); and links to similar web sites from other Federal agencies.

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Displaying 641 - 650 of 2532 Closed Funding Opportunities
Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed)
Expiration Date: Saturday, June 27, 2020
NOFO Number: RFA-NS-20-016
Monday, February 10, 2020
Notice Type: RFA
This Funding Opportunity Announcement (FOA) is aimed at discovering, characterizing the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.
Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)
Expiration Date: Thursday, January 6, 2022
NOFO Number: PAR-20-098
Thursday, February 6, 2020
Notice Type: PAR
The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.
Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)
Expiration Date: Thursday, January 6, 2022
NOFO Number: PAR-20-109
Thursday, February 6, 2020
Notice Type: PAR
The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.
Genomic Expert Curation Panels (U24 Clinical Trial Not Allowed)
Expiration Date: Friday, May 27, 2022
NOFO Number: PAR-20-101
Thursday, January 23, 2020
Notice Type: PAR
The purpose of this FOA is to establish expert panels that will select genes and genomic variants associated with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Expert Curation Panels funded through this FOA are r?e?q?u?i?r?e?d to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures, interfaces, tools and informatics infrastructure to determine the strength of evidence supporting the clinical significance of the selected genes and variants that will support development of clinical practice guidelines.
HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional)
Expiration Date: Tuesday, June 30, 2020
NOFO Number: RFA-AT-20-004
Thursday, January 23, 2020
Notice Type: RFA
This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic trial or implementation science study designs to improve pain management and reduce the use of opioid medications. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to an implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to identify effective methods to improve the management of pain and reduce the need for opioid medications at the health care system level. This FOA requires that the intervention under study be embedded into health care delivery system, real world settings. Studies can propose to integrate interventions that have demonstrated efficacy into health care system; or implement health care system changes to improve adherence to evidence-based guidelines. Trials must be conducted across two or more health care systems (HCS) and must be conducted as part of the NIH HCS Research Collaboratory supported through the NIH Common Fund. (See https://commonfund.nih.gov/hcscollaboratory). The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. After awards are made by NIH, the CCC (http://rethinkingclinicaltrials.org/about-nih-collaboratory/) and the NIH will work with successful awardees from this FOA to facilitate the planning and rapid execution of high impact trials that conduct research studies in partnerships with health care delivery systems.
HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Expiration Date: Thursday, June 25, 2020
NOFO Number: RFA-NS-20-028
Tuesday, January 21, 2020
Notice Type: RFA
The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications that propose clinical trials to test the comparative effectiveness of existing pharmacological therapies or devices for prevention or management of pain while reducing risk of addiction. The studies must evaluate methods to manage specific pain conditions that are within the mission and research interests of participating NIH Institutes and Centers, and evaluate interventions including medications, biologics, medical and assistive devices or delivery system strategies in controlled trials. This FOA does not include testing behavioral interventions for management of pain. The overall goal is to inform clinicians about the effectiveness of pharmacological or device interventions or management strategies concerning use of these interventions that reduce opioid use, improve functional outcomes and reduce pain for diseases or conditions of interest. Clinical trials will be conducted within the infrastructure of the HEAL Pain Effectiveness Research Network.
Biomedical Data Repository (U24 - Clinical Trials Not Allowed)
Expiration Date: Tuesday, May 9, 2023
NOFO Number: PAR-20-089
Friday, January 17, 2020
Notice Type: PAR
This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity.
Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed)
Expiration Date: Tuesday, May 9, 2023
NOFO Number: PAR-20-097
Friday, January 17, 2020
Notice Type: PAR
This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software and tool development are not appropriate for this activity.
Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards
Expiration Date: Monday, March 6, 2023
NOFO Number: NOT-OD-20-055
Friday, January 17, 2020
Notice Type: Notice of Special Interest
Notice Special Interest NOSI): Administrative Supplement Continuity Biomedical Behavioral Research Among First-Time Recipients NIH Research Project Grant Awards Notice Number: NOT-OD-20-055 Key Dates Release Date: January 17, 2020 First Available Due Date: March 05, 2020 Expiration Date: March 06, 2023 Related Announcements PA-18-591 Issued Office The Director, National Institutes Health OD)National Eye Institute NEI)National Heart, Lung, Blood Institute NHLBI)National Human Genome Research Institute NHGRI)National Institute Aging NIA)National Institute Alcohol Abuse Alcoholism NIAAA)National Institute Allergy Infectious Diseases NIAID)National Insrtitute Arthritis Musculoskeletal Skin Diseases NIAMS)National Institute Biomedical Imaging Bioengineering NIBIB)National Institute Deafness Other Cormmunication Disorders NIDCD)National Institute Dental Craniofacial Research NIDCR)National Institute Diabetes Digestive Kidney Diseases NIDDK)National Institute Drug Abuse NIDA)National Institute Environmental Health Sciences NIEHS)National Institute General Medical Sciences NIGMS)National Institute Mental Health NIMH)National Institute Neurological Disorders Stroke NINDS)National Institute Nursing Research NINR)National Institute Minority Health Health Disparities NIMHD)National Library Medicine NLM)National Center Complementary Integrative Health NCCIH)National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Purpose overarching goal this pilot program to enhance retention investigators facing critical life events are transitioning the first renewal their first independent research project grant award to second new NIH research project grant award. Retention the first renewal continuous NIH research project grant support crucial sustaining both ongoing research NIH made investment and retaining diversity the biomedical research workforce. program supports at-risk investigators identified the NIH Next Generation Researchers Initiative seehttps://grants.nih.gov/ngri.htm). retention program seeks maintain productivity current first-time recipients eligible independent NIH research project grant awards are dealing a critical life event(s), such they remain competitive the first renewal their award for second research project grant award. retention supplements support transition K award independence, the companion NOSI. Background Investigators, especially women, leave science critical transition stages branching points their career for NIH-supported scientific workforce include transitions post-doctoral training faculty positions Heggeness et al., 2016,Acad Med,doi:10.1097/ACM.0000000000001209and Nikaj et al., 2019, FASEB Journal,doi:10.1096/fj.201800639) prior obtaining first R01 renewal Hechtman et al., 2018, PNAS,doi:10.1073/pnas.1800615115). rate R01/R01-equiv renewals potential impact the longevity an investigators research career Pohlhaus et al., 2011,Acad Med,doi:10.1097/ACM.0b013e31821836ff) remains gender disparity NIH funding should addressed. vulnerable career stages often parallel critical life events commonly contribute faculty attrition. Data NSF demonstrates among racial ethnic groups both biomedical scientists engineers, women far likely men cite family responsibilities a reason leaving work force https://www.nsf.gov/statistics/2017/nsf17310/, especially chart 6B). Pregnancy childbirth particular, appear be significant contributors the underemployment women scientists engineers given pregnancy impact research productivity Cech Blair-Loy 2018, Changing career trajectories new parents STEM;https://www.nsf.gov/statistics/2017/nsf17310/, especially chart 6B). demands childbirth subsequent primary caregiving responsibilities necessitate changes career goals alter researchers career trajectories, depriving scientific workforce an important source talent undermining NIHs investment promising avenues new research. Retaining investigators this critical transition point protect research investment already via parent NIH award enhance diversity the investigator pool. Budget be eligible, parent award must able receive funds the time the award. administrative supplement budget request limited 1 year. Supplement budget requests cannot exceed 50,000/year direct costs, applicable F&A indirect) cost also requested. Budgets not exceed total direct costs the current parent award. Requests must reflect actual needs the proposed project. Categorical budgets permitted. Awards subject availability funds. Flexible of supplemental funds highly encouraged, may include all inclusive)computational services, supplies, equipment, supported effort additional scientific staff sustain PD/PIs research during critical life event. Eligible Individuals Program Director/Principal Investigator) PD/PIs the following activity codes eligible the program:DP1,DP2,DP5,R01,R00,R15,R21,R35,RF1, andU01and have qualifying critical life event. PD/PIs more one independent research project grant award ineligible this supplement. Qualifying Critical Life Events: PD/PI must demonstrate critical life event such childbirth adoption during parent grant project period; primary caregiving responsibilities an ailing spouse, partner, a member the immediate family. circumstances which critical life event pending is expected occur during project period, supplement period be submitted advance the event. supplements parent awards include multiple PDs/PIs, supplement be requested any the PDs/PIs accordance the existing leadership plan on behalf the PD/PI meets eligibility criteria) submitted the grantee institution the parent award. should noted for parent grant for administrative supplement, grantee the institution, the PD/PI. Application Submission Information Supplement requests must submitted accordance the parent program announcement: Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional)PA-18-591or subsequent reissued equivalent. Supplement requests must submitted electronically. process Streamlined Submissions using eRA Commons cannot used this initiative. . instructions theSF424 R&R) Application GuideandPA-18-591must followed, the following additions: Application Due Date(s) Submission dates vary awarding IC.SeeTable IC-Specific Information, Requirements Staff Contactsfor details. funding consideration, applicants must include NOT-OD-20-055 without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Research Strategy section the application limited 6 pages. R&R Project Information form, the Attachments" field: Attach Personal Statement the applicant, including long-term research objectives career goals, justification the supplemental support, a plan return full productivity the end the supplement period. Attach Institutional letter commitment includes details resources mentoring be available the applicant ensure strong productivity the parent grant. letter should also detail institutional commitment the applicants return full productivity research career trajectory the end the supplement period. is strongly recommended the applicants contact respective program officers the Institute supporting parent award confirm ahead time the supplement falls within scope the parent award. Further, applicants strongly encouraged notify program contact the Institute supporting parent award SeeTable IC-Specific Information, Requirements Staff Contacts)that request been submitted response this FOA order facilitate efficient processing the request. Administrative Review Process IC conduct administrative reviews applications submitted their IC. ICs the parent grants support most meritorious applications submitted consideration, pending availability funds. Criteria: the work/activities proposed within scope the parent award? the progress the project prior the life event adequate? the administrative supplement increase preserve likelihood the project succeed, assist candidate complete research project submit timely renewal new research project grant application? there plan the PD/PI return full productivity the end the supplement period? there strong institutional commitment e.g., protected time, policies, programs, other strategies) ensure the PD/PI maintains his/her research project independent research trajectory? Inquiries Please direct inquiries to: Melissa Ghim, PhD Office Research Womens Health ORWH) Division Program Coordination, Planning, Strategic Initiatives DPCPSI) Telephone: 301-496-7853 Email:melissa.ghim@nih.gov
Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional)
Expiration Date: Saturday, July 4, 2020
NOFO Number: RFA-HD-20-003
Thursday, January 16, 2020
Notice Type: RFA
This FOA invites applications for Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (hereafter termed "Fragile X Centers"). Successful Centers will be composed of multidisciplinary teams of investigators collaborating to address specific research priorities identified in the Strategic Plan.